ABUS
Price
$5.15
Change
+$0.03 (+0.59%)
Updated
Sep 4 closing price
Capitalization
1.02B
67 days until earnings call
Intraday BUY SELL Signals
ARRY
Price
$4.60
Change
+$0.06 (+1.32%)
Updated
Sep 4 closing price
Capitalization
706.13M
61 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ABUS vs ARRY

ABUS vs ARRY Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
ABUS vs. ARRY commentary
Sep 05, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABUS is a Buy and ARRY is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 05, 2026
Stock price -- (ABUS: $5.15 vs. ARRY: $4.60)
Brand notoriety: ABUS and ARRY are both not notable
ABUS represents the Biotechnology, while ARRY is part of the Alternative Power Generation industry
Current volume relative to the 65-day Moving Average: ABUS: 97% vs. ARRY: 48%
Market capitalization -- ABUS: $1.02B vs. ARRY: $706.13M
ABUS [@Biotechnology] is valued at $1.02B. ARRY’s [@Alternative Power Generation] market capitalization is $706.13M. The market cap for tickers in the [@Biotechnology] industry ranges from $138.42B to $0. The market cap for tickers in the [@Alternative Power Generation] industry ranges from $118.24B to $0. The average market capitalization across the [@Biotechnology] industry is $2.33B. The average market capitalization across the [@Alternative Power Generation] industry is $2.18B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ABUS’s FA Score shows that 2 FA rating(s) are green whileARRY’s FA Score has 1 green FA rating(s).

  • ABUS’s FA Score: 2 green, 3 red.
  • ARRY’s FA Score: 1 green, 4 red.
According to our system of comparison, ABUS is a better buy in the long-term than ARRY.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ABUS’s TA Score shows that 5 TA indicator(s) are bullish while ARRY’s TA Score has 3 bullish TA indicator(s).

  • ABUS’s TA Score: 5 bullish, 5 bearish.
  • ARRY’s TA Score: 3 bullish, 3 bearish.
According to our system of comparison, both ABUS and ARRY are a good buy in the short-term.

Price Growth

ABUS (@Biotechnology) experienced а +1.58% price change this week, while ARRY (@Alternative Power Generation) price change was +0.22% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.22%. For the same industry, the average monthly price growth was +5.23%, and the average quarterly price growth was +2396.59%.

The average weekly price growth across all stocks in the @Alternative Power Generation industry was -1.11%. For the same industry, the average monthly price growth was -18.18%, and the average quarterly price growth was -29.36%.

Reported Earning Dates

ABUS is expected to report earnings on Nov 11, 2026.

ARRY is expected to report earnings on Nov 05, 2026.

Industries' Descriptions

@Biotechnology (-0.22% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

@Alternative Power Generation (-1.11% weekly)

The alternative power generation industry consists of companies that operate power facilities converting non-conventional forms of energy into electricity. These energy forms are alternatives to fossil fuels, and many of them are derived from natural resources. Alternative energy forms include solar, wind, hydro, and geothermal steam. A major purpose behind using alternative energy – also called ‘clean’ energy - is to address concerns related to the more conventional fossil fuels, such as the latter’s high carbon dioxide emissions which is often considered a factor in global warming. Alternative power generation has been gaining traction in recent years, and could grow further in the future. Large organizations like Google have invested substantially in wind and solar energy-powered electricity. Some of the prominent U.S. companies operating in the alternative power generation industry includes Ormat Technologies, Inc., TerraForm Power, Inc. and NextEra Energy Partners LP.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ABUS($1.02B) has a higher market cap than ARRY($706M). ARRY has higher P/E ratio than ABUS: ARRY (56.91) vs ABUS (6.51). ABUS YTD gains are higher at: 7.069 vs. ARRY (-50.108). ABUS has higher annual earnings (EBITDA): 161M vs. ARRY (29.6M). ARRY has more cash in the bank: 201M vs. ABUS (95.2M). ABUS has less debt than ARRY: ABUS (631K) vs ARRY (763M). ARRY has higher revenues than ABUS: ARRY (1.21B) vs ABUS (191M).
ABUSARRYABUS / ARRY
Capitalization1.02B706M144%
EBITDA161M29.6M544%
Gain YTD7.069-50.108-14%
P/E Ratio6.5156.9111%
Revenue191M1.21B16%
Total Cash95.2M201M47%
Total Debt631K763M0%
FUNDAMENTALS RATINGS
ABUS vs ARRY: Fundamental Ratings
ABUS
ARRY
OUTLOOK RATING
1..100
2551
VALUATION
overvalued / fair valued / undervalued
1..100
62
Fair valued
99
Overvalued
PROFIT vs RISK RATING
1..100
60100
SMR RATING
1..100
13100
PRICE GROWTH RATING
1..100
4188
P/E GROWTH RATING
1..100
2124
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ABUS's Valuation (62) in the Biotechnology industry is somewhat better than the same rating for ARRY (99). This means that ABUS’s stock grew somewhat faster than ARRY’s over the last 12 months.

ABUS's Profit vs Risk Rating (60) in the Biotechnology industry is somewhat better than the same rating for ARRY (100). This means that ABUS’s stock grew somewhat faster than ARRY’s over the last 12 months.

ABUS's SMR Rating (13) in the Biotechnology industry is significantly better than the same rating for ARRY (100). This means that ABUS’s stock grew significantly faster than ARRY’s over the last 12 months.

ABUS's Price Growth Rating (41) in the Biotechnology industry is somewhat better than the same rating for ARRY (88). This means that ABUS’s stock grew somewhat faster than ARRY’s over the last 12 months.

ABUS's P/E Growth Rating (21) in the Biotechnology industry is in the same range as ARRY (24). This means that ABUS’s stock grew similarly to ARRY’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ABUSARRY
RSI
ODDS (%)
Bearish Trend 1 day ago
81%
Bullish Trend 1 day ago
86%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
79%
Bullish Trend 1 day ago
75%
Momentum
ODDS (%)
Bearish Trend 1 day ago
86%
Bearish Trend 1 day ago
86%
MACD
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 1 day ago
83%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
74%
Bullish Trend 1 day ago
80%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
73%
Bearish Trend 1 day ago
84%
Advances
ODDS (%)
Bullish Trend 1 day ago
74%
N/A
Declines
ODDS (%)
Bearish Trend 9 days ago
76%
Bearish Trend 5 days ago
88%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
84%
N/A
Aroon
ODDS (%)
Bullish Trend 1 day ago
75%
Bearish Trend 1 day ago
83%
View a ticker or compare two or three
Interact to see
Advertisement
ABUS
Daily Signal:
Gain/Loss:
ARRY
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
HRSCX24.27N/A
N/A
Carillon Eagle Small Cap Growth A
MFWBX19.44N/A
N/A
MFS Global Total Return B
FWTFX40.92N/A
N/A
Fidelity Advisor Worldwide M
SMNAX29.27N/A
N/A
Steward Equity Market Neutral A
FOTHX30.95N/A
N/A
Fidelity Advisor OTC I